Surgery after chemo for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent ovarian, fallopian tube, or primary peritoneal cancer that came back more than 6 months after your last platinum chemotherapy.
- You have already had 3 or 4 rounds of platinum-based chemotherapy for the recurrence and your cancer responded (shrank or stayed the same).
- You were previously told you couldn't have surgery to remove the recurrent cancer (based on the AGO score).
- You are at least 19 years old and in generally good health (able to care for yourself, up and about).
- Your blood counts, kidney, and liver function are within acceptable ranges for surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
This trial tests whether using a small-scope (minimally invasive) surgery instead of a large incision can safely remove remaining ovarian cancer after chemotherapy. It may mean a faster recovery and fewer complications.
This trial tests if a second surgery followed by heated chemotherapy delivered directly into the abdomen can help people with ovarian, fallopian tube, or peritoneal cancer whose disease has returned while on a PARP inhibitor.
This Phase 3 trial studies a three-step “extra” chemotherapy plan after surgery for people with certain advanced ovarian, fallopian-tube, or primary peritoneal cancers. The goal is to improve outcomes by lowering the chance the cancer comes back.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.